pdf

Deal Media Cover O’Melveny’s Representation of Celsion Corporation in Acquisition of EGEN

June 17, 2014 Celsion Corporation (Celsion), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, recently announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN. O'Melveny & Myers acted as legal counsel to Celsion for this transaction, which was covered in multiple publications including MergerMarket, Street Insider, and Daily Journal. O'Melveny's team was led by Menlo Park partners Jennifer DePalma and Robert Fisher, senior counsel Stanton Lovenworth in New York, senior counsel Warren Fox in San Francisco, and Menlo Park counsel Ruchun Ji.